VistaGen Therapeutics
Vistagen is dedicated to developing and commercializing a new class of intranasal product candidates called 'pherines' to establish new standards of care for psychiatric and neurological disorders. Their mission is to radically improve standards of care for highly prevalent mental health conditions, aiming for better patient outcomes through innovative neurocircuitry-focused treatments. The company is led by a visionary executive team and has a distinguished advisory board comprising experts in psychiatry, neuroscience, and drug development.
Industries
Nr. of Employees
medium (51-250)
VistaGen Therapeutics
South San Francisco, California, United States
Patents
Products
PH94B (intranasal pherine candidate for social anxiety)
Intranasal pherine investigational candidate developed for acute treatment of social anxiety disorder; in Phase 3 clinical development (PALISADE-3).
PH10 (intranasal candidate for major depressive disorder)
Intranasal investigational candidate in development for major depressive disorder.
AV-101 (clinical-stage CNS candidate)
Clinical-stage CNS investigational candidate included in the company pipeline.
Additional pipeline candidates (PH15, PH80, PH284)
Additional investigational programs in the CNS pipeline at various stages of development.
Itruvone
An odorless, tasteless synthetic investigational neuroactive pherine nasal spray designed to engage and activate chemosensory neurons in the nasal cavity for the potential treatment of major depressive disorder.
Itruvone (PH10)
An odorless synthetic investigational neuroactive pherine nasal spray designed with a novel, rapid-onset proposed mechanism of action for the potential treatment of major depressive disorder.
PH94B (intranasal pherine candidate for social anxiety)
Intranasal pherine investigational candidate developed for acute treatment of social anxiety disorder; in Phase 3 clinical development (PALISADE-3).
PH10 (intranasal candidate for major depressive disorder)
Intranasal investigational candidate in development for major depressive disorder.
AV-101 (clinical-stage CNS candidate)
Clinical-stage CNS investigational candidate included in the company pipeline.
Additional pipeline candidates (PH15, PH80, PH284)
Additional investigational programs in the CNS pipeline at various stages of development.
Itruvone
An odorless, tasteless synthetic investigational neuroactive pherine nasal spray designed to engage and activate chemosensory neurons in the nasal cavity for the potential treatment of major depressive disorder.
Itruvone (PH10)
An odorless synthetic investigational neuroactive pherine nasal spray designed with a novel, rapid-onset proposed mechanism of action for the potential treatment of major depressive disorder.
Services
End-to-end clinical development services for CNS candidates including protocol design, operational execution, and biostatistical oversight.
CMC leadership and formulation development to support clinical supply and regulatory filings for intranasal product candidates.
Regulatory planning and execution for clinical development and submissions, informed by advisors with prior regulatory review experience.
Business development and partnering activities to support collaborations, licensing, and commercialization planning.
End-to-end clinical development services for CNS candidates including protocol design, operational execution, and biostatistical oversight.
CMC leadership and formulation development to support clinical supply and regulatory filings for intranasal product candidates.
Regulatory planning and execution for clinical development and submissions, informed by advisors with prior regulatory review experience.
Business development and partnering activities to support collaborations, licensing, and commercialization planning.
Expertise Areas
- Intranasal drug delivery
- Translational neuroscience
- Clinical trial management (early- to late-phase)
- CMC and formulation development
Key Technologies
- Intranasal nose-to-brain delivery
- Neurocircuitry-targeted neuromodulation
- Preclinical rodent models (inferred)
- Magnetic resonance spectroscopy and translational imaging (inferred)